ImmunityBio Stock Soars 100% in 2026 on Blockbuster Drug Sales
ImmunityBio shares surge with 10-day winning streak as ANKTIVA cancer drug revenue jumps 700% to $113M. Saudi approval and analyst targets signal more upside ahead.
Already have an account? Sign in.